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Purpose: To investigate the correlations between parameters of dynamic contrast-en-
hanced magnetic resonance imaging (DCE-MRI) and prognostic factors in rectal can-
cer. Materials and Methods: We studied 29 patients with rectal cancer who under-
went gadolinium contrast-enhanced, T1-weighted DCE-MRI with a three Tesla 
scanner prior to surgery. Signal intensity on DCE-MRI was independently measured 
by two observers to examine reproducibility. A time-signal intensity curve was generat-
ed, from which four semiquantitative parameters were calculated: steepest slope (SLP), 
time to peak (Tp), relative enhancement during a rapid rise (Erise), and maximal en-
hancement (Emax). Morphologic prognostic factors including T stage, N stage, and 
histologic grade were identified. Tumor angiogenesis was evaluated in terms of mi-
crovessel count (MVC) and microvessel area (MVA) by morphometric study. As mo-
lecular factors, the mutation status of the K-ras oncogene and microsatellite instability 
were assessed. DCE-MRI parameters were correlated with each prognostic factor us-
ing bivariate correlation analysis. A p-value of <0.05 was considered significant. Re-
sults: Erise was significantly correlated with N stage (r=-0.387 and -0.393, respective-
ly, for two independent data), and Tp was significantly correlated with histologic grade 
(r=0.466 and 0.489, respectively). MVA was significantly correlated with SLP (r= 
-0.532 and -0.535, respectively) and Erise (r=-0.511 and -0.446, respectively). MVC 
was significantly correlated with Emax (r=-0.435 and -0.386, respectively). No signifi-
cant correlations were found between DCE-MRI parameters and T stage, K-ras muta-
tion, or microsatellite instability. Conclusion: DCE-MRI may provide useful prognos-
tic information in terms of histologic differentiation and angiogenesis in rectal cancer.
Key Words:   Colorectal neoplasms, prognosis, diagnostic imaging, magnetic reso-
nance imaging
INTRODUCTION
The prognosis of newly diagnosed colorectal cancer (CRC) depends on various 
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derwent curative surgery. Twelve patients were considered 
unresectable and underwent adjuvant chemoradiation thera-
py (CRT) before surgery. Twelve patients were excluded 
from the study due to the potential of CRT to alter the stage 
of the disease. We also excluded 2 of 31 patients with re-
sectable lesions not visualized by DCE-MRI. Therefore, 
our final study population was composed of 29 patients (20 
men and nine women; age range, 31-76 years) who under-
went curative resection of rectal cancer. We identified mor-
phologic prognostic factors including T stage, N stage, and 
histologic tumor grade based on histopathologic data. Med-
ical records were retrospectively reviewed to determine K-
ras mutation status and the presence of MSI. The study was 
approved by the institutional review board of our hospital. 
Informed consent was not required for this retrospective 
collection of patient information.
    
DCE-MRI study
DCE-MRI was obtained using a three Tesla MR Unit (Mag-
netom Tim Trio; Siemens Medical Solutions, Erlangen, Ger-
many), and a phased-array multi-coil was applied. For dy-
namic scanning, one experienced radiologist selected a 
single axial slice that contained the largest tumor area refer-
ring to unenhanced MR images. In all subjects, we ob-
tained gadolinium contrast (Gd-DTPA, Dotarem®; Guerbet, 
Nice, France)-enhanced T1-weighted dynamic imaging us-
ing a turbo fast low angle shot sequence with the following 
parameters: repetition time/echo time, 500/1.34 msec; flip 
angle, 8°; section thickness, 5 mm; number of total images, 
200; acquisition time per slice, 0.36 sec; total scan time, 72 
sec; field of view, 330 mm; and matrix, 256×125. Scanning 
was started at the intravenous administration of contrast 
agent (0.2 mL/kg of body weight) at a rate of 3 mL/s via 
the antecubital vein followed by a 20 mL saline flush using 
an automatic power injector (Spectris; Medrad, Pittsburgh, 
PA, USA). 
On DCE-MRI series in each patient, a region of interest 
(ROI) was drawn freely within the tumor to encompass the 
largest area of enhancement. The ROIs covered areas be-
tween 1.3 and 8.5 cm2. ROI measurements were indepen-
dently performed by two radiologists, generating two sets 
of data for each patient (Fig. 1). A time-signal intensity curve 
(TIC) was automatically plotted using commercially avail-
able software (Syngo; Siemens Medical Solutions, Erlan-
gen, Germany). An in-house mathematical program calcu-
lated four parameters from each curve: 1) the steepest slope 
(SLP) between two time points in a curve; 2) time to peak 
clinical, laboratory, and histopathologic factors. Tumor ex-
tent, lymph node status, histologic tumor grade, and lym-
phatic and venous invasion are established prognostic fac-
tors, and they are still the most reliable. Other recently 
investigated factors are related to biologic and molecular al-
terations in tumors, including tumor angiogenesis, excre-
tion of angiogenic cytokines, oncogene expression, and ge-
nomic alteration.1 For the evaluation of angiogenesis in 
both normal and tumor tissues, measurement of microves-
sel density (MVD) by means of immunohistochemical 
study is the most widely used method.2 Many investiga-
tions have found MVD to be a prognostic indicator of 
CRC.2-5 Several oncogenes and tumor suppressor genes are 
commonly altered in CRC, and mutations in K-ras gene are 
particularly significant.6 Complex genomic alterations are 
implicated in the tumorigenesis of gastrointestinal tract, and 
approximately 15% of CRCs have microsatellite instability 
(MSI).7 
Dynamic contrast-enhanced magnetic resonance imaging 
(DCE-MRI) can be used to measure functional vascular 
changes such as alterations in blood volume and vascular 
permeability in tumors as well as in normal tissues. Quanti-
tative or semiquantitative methods are used to analyze DCE-
MRI data. It is well established that parameters obtained 
with DCE-MRI are significantly correlated with the degree 
of angiogenesis in various malignancies.8
Although several studies9,10 have assessed tumor angio-
genesis using DCE-MRI and explored correlations with 
some parameters of clinical outcome in CRC, no studies 
have been published correlating DCE-MRI with various 
prognostic indicators in rectal cancers. Therefore, the pur-
pose of this study was to investigate the correlations be-
tween semiquantitative parameters obtained with DCE-MRI 
and morphologic, angiogenic, and molecular prognostic fac-
tors in rectal cancers.
MATERIALS AND METHODS
　　　
Patients
We analyzed data from 43 consecutive patients (30 men 
and 13 women; age range, 35-80 years) with clinically sus-
pected rectal cancer who underwent rectal MRI as part of 
their initial workup between October 2007 and March 
2008. DCE-MRI was performed as an incorporated se-
quence of MRI evaluation. Of 43 patients, 31 were diag-
nosed as resectable lesions on MRI and subsequently un-
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the values of four hot spots.  
Mutation of K-ras oncogene 
Genomic DNA was extracted from two or three four-μm-
thick de-paraffinized tissue slides, containing representative 
portions of tumor tissue. DNA extraction was performed 
using the QIAamp DNA Tissue kit (Qiagen, Hilden, Ger-
many), and 50 ng of DNA were amplified in a 20 µL reac-
tion solution (10 µL of 2× concentrated HotStarTaq Master 
Mix; Qiagen, Hilden, Germany), including polymerase 
chain reaction (PCR) buffer with 3 mM magnesium chlo-
ride (MgCl2), 400 µM deoxynucleotide triphosphates, and 
0.3 µM each of primer pair (codon 12, 13, F: 5’-CGTCTG 
CAGTCAACTGGAAT, R: 5’-GAGAATGGTCCTGCAC 
CAGTAA). PCR products were 2% gel-purified with a 
enhancement (Tp) in a curve, defined as the post-injection 
time to reach maximum signal intensity; 3) relative en-
hancement during a rapid rise (Erise), defined as SIrise-SI-
base, in which SIrise indicates signal intensity during the 
rise, and SIbase is the mean signal intensity during the ini-
tial five time points; and 4) maximum relative enhancement 
(Emax) in a TIC, defined as SImax-SIbase, where SImax 
indicates the highest signal intensity in a curve. The param-
eters of TIC are schematically displayed in Fig. 2. 
       
Morphometric analysis of microvessel density
With surgically-obtained paraffin-embedded tissue blocks, 
we selected a representative section containing tumoral and 
peritumoral tissues and prepared a four-μm-thick unstained 
slide for each patient. We performed immunohistochemis-
try with a Ventana BenchMark XT autostainer (Ventana 
Medical System Inc., Tucson, AZ, USA) according to the 
manufacturer’s protocol using a CD31-related antigen-spe-
cific mouse monoclonal antibody (1 : 20 dilution; Dako, 
Carpinteria, CA, USA). An experienced pathologist selected 
four “hot spots” of greatest vascularization per low-power 
field (40×). High-power field (200×) images of the hot spots 
were digitally photographed by a microscope (DP72; Olym-
pus, Tokyo, Japan) and stored as JPEG files (1550×1070 
pixels, 16.7 million colors, 24-bit). Any brown-stained en-
dothelial cells or endothelial cell cluster were considered a 
single, countable microvessel. Each microvessel was iden-
tified and outlined using commercialized software (Image-
Pro Plus version 4.51; Media Cybernetics Inc., Silver Spring, 
MD, USA) (Fig. 3). The total number and area of mi-
crovessels were determined for each hot spot. We then cal-
culated the mean total microvessel count (MVC) and mean 
total microvessel area (MVA) for each patient by averaging 
Fig. 2. Semiquantitative parameters of DCE-MRI in time-signal intensity 
curve. SLP is the steepest slope between two time points. Tp is time to peak 
enhancement. Relative enhancement during a rapid rise (Erise)=signal in-
tensity during the rise (SIrise)-the mean signal intensity value during the 
initial five time points (SIbase). The maximum relative enhancement 
(Emax)=the highest signal intensity value in a curve (SImax)-SIbase. SI, sig-
nal intensity; Tp, time to peak; SLP, steepest slope; DCE-MRI, dynamic con-
trast-enhanced magnetic resonance imaging.
Fig. 1. Measurement of DCE-MRI. (A) On DCE-MRI, a ROI was freely drawn within the tumor to encompass the largest area of enhance-
ment. (B) A time-signal intensity curve was generated at a workstation using commercially available software. DCE-MRI, dynamic con-
trast-enhanced magnetic resonance imaging; ROI, region of interest.
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solution contained 20 ng of purified PCR products, 1 µL of 
Big Dye Terminator, and 0.1 µM the same PCR primers as 
listed above. Sequence data were generated with the ABI 
Prism 3100 DNA Analyzer (Applied Biosystems, Foster 
City, CA, USA) and analyzed by Sequencing Analysis 5.1.1. 
software (Applied Biosystems, Foster City, CA, USA) to 
compare variations (Fig. 4).
Assessment of MSI
DNA was extracted from all matched normal and tumor tis-
sues for PCR amplification. A set of microsatellite markers 
consisting of two mononucleotide repeat markers (BAT25 
and BAT26) and three dinucleotide repeat markers (D2S123, 
D5S346, and D17S250) was used to determine tumor MSI 
status. We amplified 50 ng of DNA in 20 µL of reaction so-
lution containing 2 µL of 10× buffer (Roche, Mannheim, 
Germany), 1.7-2.5 mmol/L of MgCl2, 0.3 µM each of 
primer pairs, 250 µM deoxynucleotide triphosphate, and 
2.5 units of DNA polymerase (Roche, Mannheim, Germa-
ny). All PCR product samples were prepared for fragment 
separation on the ABI Prism 3100 Genetic Analyzer (Ap-
plied Biosystems, Foster City, CA, USA) using 0.7 μL of 
the amplified samples combined with 0.3 μL of the GeneS-
can 500 Size Standard (Applied Biosystems, Foster City, 
CA, USA) and 9 μL of HiDi formamide (Applied Biosys-
tems, Foster City, CA, USA). Electrophoresis was initiated 
when the Genetic Analyzer oven temperature equilibrated 
to 60°C. Raw data were detected in real time as the fluores-
cence was converted to digital information and were pro-
cessed at the workstation using the ABI Prism 3100 Data 
Collection software (Applied Biosystems, Foster City, CA, 
USA). Data were displayed as an electrophoregram: a plot 
of base-pair sizes displayed on the x-axis against peak sig-
QIAamp Gel Extraction Kit (Qiagen). DNA templates 
were processed for the sequencing reaction using the Big 
Dye Terminator Kit, version 3.1 (Applied Biosystems, 
Foster City, CA, USA) with both forward and reverse se-
quence-specific primers. The 10 µL sequencing reaction 
Fig. 3. Morphometric study of microvessels. Microvessels were immunostained using a CD31-related antigen-specific mouse monoclo-
nal antiboy. (A) A photomicrograph (200×) of a hot spot in a representative tumor section shows immunostained microvessels (arrows) in 
brown. (B) Microvessels are highlighted by a color threshold setting to distinguish the objects of positive staining from the counter-
stained background tissue.
Fig. 4. DNA sequencing analysis of the K-ras gene. PCR products encom-
passing codons 12 and 13 of exon 2 were analyzed to confirm mutations. 
An overlap (arrow) of black G- and red T peaks at codon 12 is shown, rep-
resenting a substitution of valine for glycine with G to T transversion. PCR, 
polymerase chain reaction.
Fig. 5. A plot of electrophoregram analysis of microsatellite instability. The 
data of normal control (upper row) and tumor tissue (lower row) are dis-
played as base-pair size displayed on the x-axis against peak signal inten-
sity in relative fluorescent units on the y-axis. A single, small peak (arrow) 
is additionally seen in tumor only with D17S250 marker, representing low-
frequency of microsatellite instability (MSI-low). 
A B
Codon 12, 13
BAT26
N
or
m
al
Tu
m
or
BAT25D5S346 D17S250 D2S123
70 8075 85 90
100
1600
1200
2700
800
1800
400
900
0
0
150 200
DCE-MRI in the Prognostication of Rectal Cancer
Yonsei Med J   http://www.eymj.org   Volume 54   Number 1   January 2013 127
The distribution of each morphologic factor and the val-
ues of each angiogenic marker are provided in Table 1. In 
the analysis of the K-ras mutation, mutant type was found 
in 6 of the 29 patients. In the 6 tumors, mutated K-ras was 
found in codons 12 and 13 located in exon 2. Four showed 
mutations at codon 12; a substitution of valine for glycine 
involving a base position (bp) 35 guanine-to-thymidine 
change (G to T transversion) in 2 and serine for glycine in-
volving bp 34 guanine-to-adenine (G to A transition) in 2. 
The remaining two affected codon 13 with a substitution of 
aspartic acid for glycine, bp 38 G to A transition. Of the 29 
patients, only one showed a low-frequency of microsatellite 
alteration (MSI-low), in which a single peak was observed 
only with D17S250 marker (Fig. 5). The remaining 28 
showed microsatellite stable. Table 2 summarizes the corre-
lations of DCE-MRI with morphologic and angiogenic 
prognostic factors. For both observers, Tp was positively 
correlated with histologic tumor grade (r=0.466, p=0.01; 
r=0.489, p=0.01; respectively), i.e. poorly differentiated tu-
mors showed longer time to reach the peak enhancement 
compared with that of well differentiated lesions. Erise was 
negatively correlated with N stage for both observers (r= 
-0.387, p=0.04; r=-0.393, p=0.03; respectively). In the cor-
relations between DCE-MRI and tumor angiogenesis, for 
both observers, MVA was significantly correlated with SLP 
(r= -0.532, p=0.003; r=-0.511, p=0.005; respectively) and 
Erise (r=-0.535, p=0.003; r=-0.446, p=0.015; respectively). 
nal intensity (peak height) in relative fluorescent units on 
the y-axis (Fig. 5).
Statistical analysis
Bivariate Spearman correlation analysis was performed to 
investigate the correlations between DCE-MRI parameters 
and prognostic factors. The correlation coefficient (rho, r) 
was calculated and considered to be statistically significant 
when the two-tailed p-value was less than 0.05. To test the 
reproducibility of DCE-MRI measurements independently 
obtained by two observers, intra-class correlation coeffi-
cient (ICC) values for the parameters of two DCE-MRI 
data sets were calculated with a 95% confidence interval 
(CI). Data processing and statistical analysis were per-
formed using the SPSS 18.0 statistical program (SPSS Inc., 
Chicago, IL, USA).
 
RESULTS
 
SLP ranged 0.43-2.17 (mean±SD, 1.19±0.49) for observer 1 
and 0.33-2.08 (1.14±0.48) for observer 2. Tp ranged 21.24-
70.56 sec (47.50±19.12) and 20.52-70.56 sec (47.71±18.94) 
for the two observers, respectively. Erise ranged 22.22-
94.21 (47.00±17.56) and 17.00-91.46 (45.49±18.41), re-
spectively, and Emax was 22.90-99.43 (52.57±20.07) and 
17.11-98.28 (50.25±22.02), respectively.
Table 1. Distribution of the Values in Morphologic and Angiogenic Prognostic Factors
Morphologic factors                           Angiogenic factors
T N Histologic grade MVC MVA      
T1 (1)   N0 (13) Well differentiated (4) 5.0-20.5 0.3-31.2    
T2 (6) N1 (8) Moderate (24)
  T3 (20) N2 (8) Poor (1)
T4 (2)
T, T stage; N, N stage; MVC, mean total microvessel count per field (40×); MVA, mean total microvessel area per field (40×).
Numbers in parenthesis are numbers of patients.
Table 2. Correlations of DCE-MRI with Morphologic and Angiogenic Factors
Observer 1 Observer 2
T N Grade MVC MVA T N Grade MVC MVA   
SLP   0.003 -0.238 -0.089 -0.347   -0.532*  0.008 -0.266 0.007 -0.341  -0.511*   
Tp -0.041  0.025     0.466* -0.256  0.150 -0.044  0.029   0.489* -0.270  0.038   
Erise -0.059   -0.387* -0.018 -0.357   -0.535* -0.071   -0.393* 0.160 -0.367   -0.446*  
Emax -0.002 -0.213  0.162   -0.435* -0.353 -0.039 -0.267 0.267   -0.386* -0.354   
T, T stage; N, N stage; Grade, histologic grade; MVC, mean total microvessel count per field (40×); MVA, mean total microvessel area per field (40×); SLP, 
steepest slope; Tp, time to peak enhancement; Erise, relative enhancement during a rapid rise; Emax, relative maximum enhancement; DCE-MRI, dynamic 
contrast-enhanced magnetic resonance imaging. 
Data are correlation coefficients (rho, r) obtained by bivariate Spearman correlation analysis.
*Statistically significant (p<0.05) for both observers.
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reflect functional status. DCE-MRI has shown high correla-
tion with MVD14-16 and is capable of depicting functional 
vascular changes such as alterations in blood volume and 
vascular permeability in many tumors.8,17-19 Many studies 
have described the promising role of DCE-MRI in evaluat-
ing tumor angiogenesis in various human malignancies16,20,21 
including CRC.9,10 Our study also showed significant corre-
lations between parameters of DCE-MRI and tumor angio-
genesis quantified by microvessel count and area in patients 
with rectal cancer. 
Among the DCE-MRI parameters in our study, time to 
peak enhancement was significantly correlated with histo-
logic tumor grade. A similar correlative study by Tuncbilek, 
et al.10 found that histologic grade was significantly corre-
lated with steepest slope and maximal enhancement of 
DCE-MRI, but not with time to peak, differing from our re-
sults. Semiquantitative parameters of DCE-MRI are ob-
tained by interpreting changes in signal intensity as a func-
tion of time displayed by a curve, i.e., curvology. These 
parameters are indirectly related to changes in perfusion be-
cause there is no simple relation between changes in signal 
intensity and tissue concentration of contrast media. MRI 
signal intensity is dependent on many factors, including na-
tive tissue relaxation rates, contrast agent dose, injection 
rate, choice of imaging sequence and parameters, machine 
gain, and scaling factors.22 Therefore, semiquantitative re-
sults are not readily applicable from one institution to an-
other, because of different imaging equipment and proto-
col.23,24 The advantage of semiquantitative analysis is that it 
is relatively simple in estimating with T1-weighted MRI, 
whereas quantitative analysis requires conversion of MRI 
signal intensities to contrast concentration by complex 
pharmacokinetic modeling.10 Another advantage of semi-
quantitative parameters is their high reproducibility, as 
shown in our results as well as those in the literature.23 Cur-
rently, DCE-MRI has been standardized with several quan-
titative parameters25 and used as a noninvasive imaging 
biomarker to measure the properties of tumor microvascu-
lature. 
In our study, N stage showed a negative correlation with 
Erise. Tumors with more advanced N stages showed less 
enhancement during the interval of rapid rise in signal in-
tensity, compared with those with earlier stages. We cannot 
exactly explain the mechanism of this negative correlation, 
however, the semiquantitative parameter “Erise” does not 
necessarily mean the quantity or total amount of perfusion. 
DCE-MRI parameters represent physiologic properties of 
MVC was significantly correlated with Emax for both ob-
servers (r=-0.435, p=0.02; r=-0.386, p=0.04; respectively). 
None of the imaging parameters were significantly correlat-
ed with K-ras mutations or presence of MSI for either ob-
server. 
In the evaluation of inter-observer agreement for the in-
dependent sets of DCE-MRI parameters, ICC values for 
each parameter showed almost perfect level of agreement; 
0.902 (0.802-0.953, 95% CI) for SLP, 0.902 (0.802-0.953, 
95% CI) for Tp, 0.916 (0.829-0.960, 95% CI) for Erise, and 
0.911 (0.819-0.957, 95% CI) for Emax.
DISCUSSION
The prognosis of newly diagnosed CRC predicts not only 
long-term clinical outcome, but also determines treatment 
strategy and patient selection for optimal therapy. The esti-
mation of prognosis largely relies on the morphologic or 
anatomic extent of disease based on established staging 
classifications. The tumor node metastasis staging system 
remains the gold standard of prognostic factors in CRC.1 
However, heterogeneous outcomes and different responses 
to therapy among patients with histologically identical stag-
es have prompted investigations into biologic and molecu-
lar tumor alterations as additional factors in prognosis. Pre-
vious research has shown that the degree of angiogenesis is 
related to tumor progression, lymph node and liver metasta-
ses, and survival in CRC.2,3,11 K-ras mutations have been 
identified in 40-50% of CRCs; several reports have linked 
genotypic alterations of K-ras to stratification of progno-
sis.6,12 Approximately 15% of CRCs exhibit MSI, which is 
characterized by the inactivation of a mismatch repair gene 
and is currently being investigated as one of the promising 
molecular markers of outcome. According to a meta-analy-
sis by Popat, et al.,7 CRC patients with MSI were found to 
have a significantly better prognosis compared to those 
with intact mismatch repair genes. 
Quantification of tumor angiogenesis is typically as-
sessed by counting microvessels in immunostained tissue 
sections. This technique is invasive and requires biopsy or 
surgery for tissue sampling. Other drawbacks are inherent 
inter-observer variability in selecting vascular hot spots, 
technical limitations such as sampling bias, and method-
ological discrepancies in the use of antibodies for immu-
nostaining and counting vessels.13 MVD count is a static 
structural assessment of the microvasculature that does not 
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tumor microvasculature such as rapidity of blood flow or 
permeability in vivo. In our study, we defined Erise as an en-
hancement of a certain interval during the scan, consequent-
ly, it may not indicate the amount of perfusion. To our best 
knowledge, this is the first observation in evaluating correla-
tions of DCE-MRI parameters with morphologic prognostic 
factors in primary adenocarcinoma of the rectum. 
We found no significant correlations between DCE-MRI 
and molecular factors. It may be attributed to a small num-
ber of positive samples in the molecular data, which might 
have produced misleading result. Further studies with larg-
er number of patietns would better be able to detect signifi-
cant results.
Our study has several limitations. First, the study popula-
tion was relatively small in number, resulting in suboptimal 
power to detect differences. As previously mentioned, a few 
positive data in molecular prognostic factors might have in-
fluenced statistical analysis. Second, DCE-MRI data were 
analyzed by a semiquantitative method that is indirect in 
representing tissue perfusion and is not standardized among 
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MRI parameters in our study were not explored according 
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by retrospective analysis of patient data. The patient popu-
lation included heterogeneous subgroups of CRC stages. 
Although significant results were obtained between DCE-
MRI, morphologic nodal status, and histologic tumor grade, 
a larger cohort study of patients with identical CRC stage is 
warranted to investigate the correlations between imaging 
parameters and molecular markers.
In conclusion, some parameters of DCE-MRI showed 
significant correlations with N stage, histologic tumor grade, 
and degree of tumor angiogenesis. Although the measure-
ment was semiquantitative and thus indirectly represents 
tumor microvasculature, DCE-MRI may provide useful 
prognostic information in terms of histologic differentiation 
and angiogenesis in rectal cancer. 
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